David Lapointe's Contact Details

David Lapointe's Company Details

Optina Diagnostics

Montreal, QC, CA • 20 - 49 Employees
SaaS

Optina's Retinal Deep Phenotyping platform addresses the major challengesfaced by the healthcare system related to an aging population. Recently, Optina was granted breakthrough device designation by the FDA forour first indication in Alzheimer's Disease detection which enables a dramaticimprovement in the diagnostic accuracy of dementia. Our ecosystem comprised of a proprietary platform and a network of eye clinicscreates a new and efficient means for simple patient stratification. Theecosystem allows for the collection of data rich retinal images with 30X moreinformation than current retinal imaging platforms. Algorithm development utilizes a ground truth that is based on specificallycharacterized patients from leading institutions around the world. With our developing product pipeline, Optina continues to bring clarity andaccessibility to early stage diagnosis, improving the life of millions.